STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNDM
  4. [Form 4] TANDEM DIABETES CARE INC Insider Trading Activity

29,136 RSUs granted to Tandem Diabetes Care (TNDM) chief operating officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.

Tandem Diabetes Care executive vice president and chief operating officer Jean-Claude Kyrillos received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.

One-third of these RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms. Following this grant, Kyrillos directly holds 29,136 RSUs linked to common stock.

Positive

  • None.

Negative

  • None.
Insider Kyrillos Jean-Claude
Role EVP & Chief Operating Officer
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 29,136 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 29,136 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.
RSUs granted 29,136 units Restricted stock units granted to EVP & COO on May 29, 2026
RSUs underlying shares 29,136 shares Common stock underlying the RSU grant
Post-grant RSU holdings 29,136 units Total RSUs held directly following the reported transaction
Initial vesting date May 29, 2027 One-third of RSUs vest on this date under the 2023 Plan
Remaining vesting pattern 8 quarterly installments Balance of RSUs vest in eight equal quarterly installments thereafter
Restricted Stock Unit financial
"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
contingent right financial
"Each restricted stock unit (RSU) represents a contingent right to receive either one share..."
2023 Long-Term Incentive Plan financial
"in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan..."
vest financial
"One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kyrillos Jean-Claude
(Last)(First)(Middle)
12400 HIGH BLUFF DRIVE
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)05/29/2026A29,136 (2) (2)Common Stock29,136$029,136D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
2. One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.
Remarks:
Ex. 24: Power of Attorney
/s/ Jerilyn Laskie, Attorney-in-Fact for Jean-Claude Kyrillos06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tandem Diabetes Care (TNDM) report for Jean-Claude Kyrillos?

Tandem Diabetes Care reported that EVP and COO Jean-Claude Kyrillos received a grant of 29,136 restricted stock units. These RSUs were awarded as part of the company’s 2023 Long-Term Incentive Plan and are settled in stock or cash at the company’s discretion.

How many restricted stock units did TNDM grant to its COO?

The COO of Tandem Diabetes Care, Jean-Claude Kyrillos, was granted 29,136 restricted stock units. Each unit is tied to one share of common stock or cash and is subject to a multi-year vesting schedule under the 2023 Long-Term Incentive Plan.

What is the vesting schedule for Jean-Claude Kyrillos’ 29,136 RSUs at Tandem Diabetes Care?

One-third of the 29,136 RSUs will vest on May 29, 2027. The remaining two-thirds will then vest in eight equal quarterly installments on the 15th of the month, all subject to the terms of Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.

What does each RSU granted to TNDM’s COO represent?

Each restricted stock unit granted to TNDM’s COO represents a contingent right to receive either one share of Tandem Diabetes Care common stock or cash. Settlement form is at the company’s discretion and governed by the 2023 Long-Term Incentive Plan and related agreements.

How many RSUs does Jean-Claude Kyrillos hold after this Form 4 transaction?

After this transaction, Jean-Claude Kyrillos directly holds 29,136 restricted stock units. These RSUs are derivative securities linked to Tandem Diabetes Care common stock and will convert into shares or cash as they vest under the plan’s terms over time.

Under which plan were the RSUs for Tandem Diabetes Care’s COO granted?

The RSUs were granted under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended. This plan governs key terms such as settlement in stock or cash, vesting schedule, and other conditions tied to executive equity compensation awards.